Obligacje GS71
Poniżej znajduje się lista obligacji korporacyjnych GSK PLC. Inwestorzy często wybierają obligacje spółek ze względu na ich zwiększoną stabilność w czasach zmienności rynkowej. Przeanalizuj ceny, rentowności i inne statystyki, aby znaleźć wiarygodną inwestycję.
Symbol | YTM % | Wolumen | Cena % | Kupon % | Termin zapadalności | Kwota niezapłacona | Wartość nominalna | Min. kw. nominału | Emitent |
|---|---|---|---|---|---|---|---|---|---|
| 117RIGLAXOSMITHKLINE CAPITAL PLC 4.25% GTD SNR EMTN 18/12/45 | 5,57% | 8,46 K | 82,51% | 4,25% | 2045-12-18 | 370,786 M GBP | 1 000,00 GBP | 100 000,00 GBP | GlaxoSmithKline Capital Plc |
| 883GIGLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 10/04/2042 | 5,31% | 0 | 99,28% | 5,25% | 2042-04-10 | 477,816 M GBP | 1 000,00 GBP | 50 000,00 GBP | GlaxoSmithKline Capital Plc |
| 771ZCGLAXOSMITHKLINE CAPITAL PLC 6.375% GTD SNR EMTN 09/03/39 | 5,25% | 0 | 111,75% | 6,38% | 2039-03-09 | 631,3 M GBP | 1 000,00 GBP | 50 000,00 GBP | GlaxoSmithKline Capital Plc |
| GGSK3981911GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043 | 5,24% | 15 K | 87,07% | 4,20% | 2043-03-18 | 500 M USD | 1 000,00 USD | 2 000,00 USD | GlaxoSmithKline Capital, Inc. |
| GGSK.GJGlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038 | 5,21% | 5,11 M | 111,65% | 6,38% | 2038-05-15 | 2,75 B USD | 1 000,00 USD | 2 000,00 USD | GlaxoSmithKline Capital, Inc. |
| XXS217060907GLAXOSM.CAP. MTN 20/35MTN | 4,96% | 0 | 72,22% | 1,63% | 2035-05-12 | 750 M GBP | 1 000,00 GBP | 100 000,00 GBP | GlaxoSmithKline Capital Plc |
| AAG99GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 19/12/2033 | 4,73% | 0 | 103,93% | 5,25% | 2033-12-19 | 574,166 M GBP | 1 000,00 GBP | 1 000,00 GBP | GlaxoSmithKline Capital Plc |
| 772WIGLAXOSMITHKLINE CAPITAL INC 5.375% GTD SNR NTS 15/04/2034 | 4,69% | 8 K | 105,28% | 5,38% | 2034-04-15 | 500 M USD | 1 000,00 USD | 1 000,00 USD | GlaxoSmithKline Capital, Inc. |
| UUS377373AH8GLAXOSM.CAP. 19/29 | 4,63% | 0 | 94,82% | 3,38% | 2029-06-01 | 1 B USD | 1 000,00 USD | 2 000,00 USD | GlaxoSmithKline Capital Plc |
| UUS377372AN7GLAXOSMITHKLINE CAP.18/28 | 4,57% | 0 | 97,75% | 3,88% | 2028-05-15 | 1,75 B USD | 1 000,00 USD | 2 000,00 USD | GlaxoSmithKline Capital, Inc. |
| XXS217060184GLAXOSM.CAP. MTN 20/28MTN | 4,47% | 0 | 88,41% | 1,25% | 2028-10-12 | 750 M GBP | 1 000,00 GBP | 100 000,00 GBP | GlaxoSmithKline Capital Plc |
| GGSK4632357GlaxoSmithKline Capital, Inc. 3.625% 15-MAY-2025 | 3,97% | 228 K | 99,66% | 3,63% | 2025-05-15 | 1 B USD | 1 000,00 USD | 2 000,00 USD | GlaxoSmithKline Capital, Inc. |
| GGX5CGLAXOSM.CAP. MTN 05/25 | 3,30% | 0 | 100,69% | 4,00% | 2025-06-16 | 750 M EUR | 1 000,00 EUR | 1 000,00 EUR | GlaxoSmithKline Capital Plc |
| XXS255381776GSK CAP B.V. 22/32 MTN | 3,05% | 0 | 100,51% | 3,13% | 2032-11-28 | 700 M EUR | 1 000,00 EUR | 100 000,00 EUR | GSK Capital BV |
| XXS182282979GLAXOSM.CAP. MTN 18/30MTN | 2,82% | 0 | 94,50% | 1,75% | 2030-05-21 | 750 M EUR | 1 000,00 EUR | 100 000,00 EUR | GlaxoSmithKline Capital Plc |
| XXS255381768GSK CAP B.V. 22/27 MTN | 2,66% | 0 | 100,99% | 3,00% | 2027-11-28 | 500 M EUR | 1 000,00 EUR | 100 000,00 EUR | GSK Capital BV |
| XXS168152035GLAXOSM.CAP. MTN 17/29 | 2,63% | 0 | 94,28% | 1,38% | 2029-09-12 | 500 M EUR | 1 000,00 EUR | 100 000,00 EUR | GlaxoSmithKline Capital Plc |
| GGX5BGLAXOSM.CAP. MTN 17/26 | 2,53% | 0 | 97,25% | 1,00% | 2026-09-12 | 700 M EUR | 1 000,00 EUR | 100 000,00 EUR | GlaxoSmithKline Capital Plc |
| XXS182282812GLAXOSM.CAP. MTN 18/26MTN | 2,53% | 0 | 98,09% | 1,25% | 2026-05-21 | 1 B EUR | 1 000,00 EUR | 100 000,00 EUR | GlaxoSmithKline Capital Plc |
| XXS114760579GLAXOSM.CAP. MTN 14/24 | 1,45% | 0 | 99,93% | 1,38% | 2024-12-02 | 1 B EUR | 1 000,00 EUR | 100 000,00 EUR | GlaxoSmithKline Capital Plc |
| 117RNGLAXOSMITHKLINE CAPITAL PLC 3.375% GTD SNR EMTN 20/12/2027 | −0,52% | 0 | 112,19% | 3,38% | 2027-12-20 | 307,77 M GBP | 1 000,00 GBP | 100 000,00 GBP | GlaxoSmithKline Capital Plc |
| AAQ72GLAXOSMITHKLINE CAPITAL PLC 0.883% GTD SNR EMTN 21/09/20 | — | — | — | 0,88% | 2028-09-21 | 42,5 B JPY | 100 000 000,00 JPY | — | GlaxoSmithKline Capital Plc |